TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A MedPage Today neurology roundup published Oct. 27, 2026, summarized three studies on head shape and Alzheimer’s pathology, prenatal phosphatidylcholine and children’s outcomes, and platelet genetics that may affect aspirin’s relationship with dementia prevention. The findings are preliminary or limited to specific study designs; they do not establish that head shape causes Alzheimer’s disease, that choline supplements raise IQ generally, or that aspirin prevents dementia.
MedPage Today published a neurology research roundup on Oct. 27, 2026, highlighting studies that examined whether head shape relates to Alzheimer’s pathology, whether prenatal phosphatidylcholine affects children’s development, and whether genetic differences may alter aspirin’s potential relationship with dementia. The findings point to research questions rather than settled clinical guidance: the supplied report does not establish that head shape causes Alzheimer’s disease or that aspirin prevents dementia.
The roundup listed a study published in Alzheimer’s & Dementia under the question of whether head shape can influence Alzheimer’s disease pathology. The summary provided by MedPage Today did not describe the study’s methods, results, or the specific association observed. It therefore supports reporting that the topic was investigated, but not a conclusion that head shape changes disease risk or pathology.
A separate randomized trial, reported in the American Journal of Obstetrics and Gynecology, found that prenatal phosphatidylcholine supplements were associated with fewer social-withdrawal problems and higher IQ test performance in offspring through age 4. The report said the intervention did not reduce attention problems. It supplied no effect sizes or details about the number of participants, so the size and broader applicability of the findings cannot be assessed from this roundup alone.
For aspirin, MedPage Today summarized an analysis of ASPREE trial data published in Alzheimer’s & Dementia. Platelet-count polygenic scores may influence how aspirin relates to dementia prevention, the report said, raising the possibility that outcomes differ among subgroups of older adults. This is a suggestion from an analysis, not evidence in the supplied material that aspirin prevents dementia or that clinicians should use genetic scores to guide treatment.
What the Findings Could Mean
Together, the three items show how dementia and child-development research is examining factors that may shape risk or outcomes, from biological traits to prenatal nutrition and genetic variation. The aspirin analysis is relevant to older adults because it raises the possibility that treatment effects could differ across groups. But the roundup does not show that a subgroup has a proven benefit, identify who might qualify, or establish a change in clinical practice.
The prenatal trial may interest families and clinicians because it reports measured outcomes in children through age 4. Its findings are specific to the intervention and outcomes studied; they do not establish a general IQ benefit from supplements, effects beyond age 4, or a basis for individuals to start supplementation. The head-shape item, meanwhile, signals an area of investigation but offers too little detail in the source summary to judge its practical implications.
Products Worth Considering
Withings Body Scan Smart Scale with Segmental Body Composition and ECG, Black
Oral-B iO Series 5 Rechargeable Electric Toothbrush with Travel Case and 3 Brush Heads, Black
Hyperice Normatec Elite Wireless Compression Boots Recovery – Standard Size
As an affiliate, we earn on qualifying purchases.
Three Separate Research Questions
The three findings come from separate studies and should not be treated as one coordinated investigation. MedPage Today’s Oct. 27 report was a brief roundup of neurology and neuroscience developments, rather than a full account of each paper. It also included other research topics, but the three studies covered here concern head shape, prenatal phosphatidylcholine, and aspirin-related dementia analysis.
The roundup’s wording is cautious on the aspirin question: platelet-count genetic scores “may influence” aspirin’s potential role. Likewise, it presents the head-shape item as a research question and reports specific outcomes—not a broad claim—about the prenatal trial. The underlying publications and their full methods would be needed to assess study populations, limitations, and the strength of each result.
“Can head shape influence Alzheimer’s disease pathology?”
— MedPage Today’s summary of the head-shape study
Limits of the Reported Evidence
The source summary does not provide the head-shape study’s findings or explain how the researchers measured head shape and Alzheimer’s pathology. It also omits details needed to evaluate the prenatal trial, including participant numbers, effect sizes, and whether the reported differences persisted after age 4. For the aspirin analysis, the summary does not identify which genetic-score groups might differ, the size of any effects, or whether the analysis supports a treatment recommendation.
These distinctions matter: an observed association or subgroup signal does not by itself establish cause or show that an intervention will help an individual. The material provided also does not state whether the findings have been independently replicated. No medical advice should be inferred from the roundup alone.
Full Studies and Follow-Up
The next step for readers seeking to assess the claims is to consult the full papers in Alzheimer’s & Dementia and the American Journal of Obstetrics and Gynecology, including their methods, participant details, and limitations. Further research would be needed to test whether the head-shape relationship is reproducible, whether the prenatal trial’s results persist as children grow, and whether platelet-count genetic scores reliably identify different aspirin outcomes.
The supplied report does not announce a clinical guideline change or specify a timetable for follow-up results. Until more evidence is available, the findings should be treated as research developments, not as grounds to start, stop, or change aspirin or prenatal supplements without discussing medical decisions with a qualified professional.
Key Questions
Does the report show that head shape causes Alzheimer’s disease?
No. It says a study examined whether head shape can influence Alzheimer’s pathology, but the supplied summary does not give the study’s results or establish causation.
Did prenatal phosphatidylcholine improve every outcome measured?
No. The roundup reports fewer social-withdrawal problems and higher IQ test performance through age 4, but says attention problems did not decrease.
Does the aspirin analysis prove aspirin prevents dementia?
No. It suggests platelet-count polygenic scores may affect aspirin’s potential relationship with dementia. The summary does not establish that aspirin prevents dementia or identify a proven beneficiary group.
Should people change aspirin or supplement use based on these findings?
The roundup does not provide treatment guidance. People should discuss medication or supplement decisions with a qualified health professional.
Source: rss
